J Med Internet Res. 2023;25:e45760.
Diagnostic Value of a Wearable Continuous Electrocardiogram Monitoring Device (AT-Patch) for New-Onset Atrial Fibrillation in High-Risk Patients: Prospective Cohort Study.
제1저자 권주성 · 교신저자 윤창환
소속 (3)
- Cardiovascular Center, Seoul National University Bundang Hospital, Seongnam-si, Republic of Korea.
- Department of Internal Medicine, Kyungpook National University Hospital, Daegu, Republic of Korea.
- Department of Internal Medicine, Sihwa Medical Center, Siheung-si, Republic of Korea.
Abstract
BACKGROUND While conventional electrocardiogram monitoring devices are useful for detecting atrial fibrillation, they have considerable drawbacks, including a short monitoring duration and invasive device implantation. The use of patch-type devices circumvents these drawbacks and has shown comparable diagnostic capability for the early detection of atrial fibrillation.
OBJECTIVE We aimed to determine whether a patch-type device (AT-Patch) applied to patients with a high risk of new-onset atrial fibrillation defined by the congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, stroke, vascular disease, age 65-74 years, sex scale (CHA2DS2-VASc) score had increased detection rates.
METHODS In this nonrandomized multicenter prospective cohort study, we enrolled 320 adults aged ≥19 years who had never experienced atrial fibrillation and whose CHA2DS2-VASc score was ≥2. The AT-Patch was attached to each individual for 11 days, and the data were analyzed for arrhythmic events by 2 independent cardiologists.
RESULTS Atrial fibrillation was detected by the AT-Patch in 3.4% (11/320) of patients, as diagnosed by both cardiologists. Interestingly, when participants with or without atrial fibrillation were compared, a previous history of heart failure was significantly more common in the atrial fibrillation group (n=4/11, 36.4% vs n=16/309, 5.2%, respectively; P=.003). When a CHA2DS2-VASc score ≥4 was combined with previous heart failure, the detection rate was significantly increased to 24.4%. Comparison of the recorded electrocardiogram data revealed that supraventricular and ventricular ectopic rhythms were significantly more frequent in the new-onset atrial fibrillation group compared with nonatrial fibrillation group (3.4% vs 0.4%; P=.001 and 5.2% vs 1.2%; P<.001), respectively.
CONCLUSIONS This study detected a moderate number of new-onset atrial fibrillations in high-risk patients using the AT-Patch device. Further studies will aim to investigate the value of early detection of atrial fibrillation, particularly in patients with heart failure as a means of reducing adverse clinical outcomes of atrial fibrillation.
TRIAL REGISTRATION ClinicalTrials.gov NCT04857268; https://classic.clinicaltrials.gov/ct2/show/NCT04857268.
©Ju-Seung Kwun, Jang Hoon Lee, Bo Eun Park, Jong Sung Park, Hyeon Jeong Kim, Sun-Hwa Kim, Ki-Hyun Jeon, Hyoung-won Cho, Si-Hyuck Kang, Wonjae Lee, Tae-Jin Youn, In-Ho Chae, Chang-Hwan Yoon. Originally published in the Journal of Medical Internet Research (https://www.jmir.org), 18.09.2023.
Keywords
AT-Patchadultarrhythmiasatrial fibrillationelectrocardiogramheart failuremobile phonepatch electrocardiogram monitorwearable electronic device
Figures
그림 출처: PubMed Central 공개 논문 (PMC10546264)
Conflict of interest statement
Conflicts of Interest: CHY owns stock in ATsens. Other authors declare no financial or nonfinancial competing interests.
그 밖의 정보
- 출판 형태
- Multicenter Study, Journal Article, Research Support, Non-U.S. Gov't
- 저널
- Journal of medical Internet research · eISSN 1438-8871
- 전자 출판
- 2023-09-18
- MeSH
- Adult · Humans · Atrial Fibrillation* / diagnosis · Prospective Studies · Electrocardiography · Heart Failure* / diagnosis · Wearable Electronic Devices*
- 데이터
- ClinicalTrials.gov: NCT04857268
- 참고문헌
- 26편